TY - JOUR
T1 - Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce
AU - Musters, A. H.
AU - Gerbens, L. A. A.
AU - van der Gang, L.
AU - Middelkamp-Hup, M. A.
AU - Ouwerkerk, W.
AU - Hijnen, D. J.
AU - Haufe, E.
AU - Heinrich, L.
AU - Werfel, T.
AU - Weidinger, S.
AU - Schmitt, J.
AU - Svedbom, A.
AU - Johansson, E. K.
AU - Bradley, M.
AU - von Kobyletzki, L. B.
AU - Vittrup, I.
AU - Ruge, I. F.
AU - Thyssen, J. P.
AU - Vestergaard, C.
AU - Carrascosa, J. M.
AU - de Vega, M.
AU - García-Doval, I.
AU - Chiricozzi, A.
AU - Stingeni, L.
AU - Calzavara-Pinton, P.
AU - Ardern-Jones, M. R.
AU - Reynolds, N. J.
AU - Flohr, C.
AU - Spuls, P. I.
AU - the A-STAR, AtopyReg, BIOBADATOP, SCRATCH, SwedAD, TREATgermany and TREAT NL/BE registry teams
AU - Bosma, Angela
AU - Caron, Anouk
AU - Hyseni, Ariënna
AU - Dijkstra, Jitske
AU - Nguyen, Ly
AU - de Schepper, Sofie
AU - Lapeere, Hilde
AU - de Waele, David
AU - Beattie, Paula
AU - Brown, Sara
AU - Burton, Tim
AU - Ingram, John
AU - Irvine, Alan
AU - Johnston, Graham
AU - Man, Irene
AU - Manca, Andrea
AU - Ogg, Graham
AU - Patton, Thomas
AU - Wan, Mandy
AU - Warren, Richard
AU - Woolf, Richard
AU - Baden, Manisha
AU - Prieto-Merino, David
AU - Malik, Rayka
AU - Coker, Bola
AU - de la Cruz, Lilia
AU - Gribaleva, Elizaveta
AU - Begum, Tanzeem
AU - Descalzo, Miguel Angel
AU - Flórez, Ángeles
AU - Arnau, Ana María Giménez
AU - Quesada, Alicia González
AU - Silvestre, Juan Francisco
AU - Serna, Mercedes Rodríguez
AU - Chicharro, Pablo
AU - Gilaberte, Yolanda
AU - de la Cueva, Pablo
AU - Montero, Trini
AU - González, Marta Elosua
AU - Villaverde, Ricardo Ruiz
AU - Rodríguez, José Juan Pereyra
AU - Cebey, Ana Batalla
AU - Arias, Martina Espasandin
AU - Rodríguez, Carmen Couselo
AU - Curto, Laia
AU - Bertolín, Marta
AU - Castaño, Irene
AU - Betlloch, Isabel
AU - Pérez, Miguel Antonio Lasheras
AU - Pérez, Javier Abilio S. nchez
AU - Ruiz, Adrián Ballano
AU - Munera, M. nica
AU - Arias-Santiago, Salvador
AU - Roustan, Gastón
AU - de la Torre, Raquel Sanabria
AU - Diaz, Angel Rosell
AU - Carrascosa, José Carlos Ruiz
AU - Navarro Triviño, Francisco J.
AU - Elberling, Jesper
AU - Skov, Lone
AU - Ibler, Kristina
AU - Jemec, Gregor
AU - Möertz, Charlotte
AU - Bindslev-Jensen, Carsten
AU - Kamstrup, Maria
AU - Egeberg, Alexander
AU - Deleuran, Mette
AU - Alsterholm, Mikael
AU - Anderson, Chris D.
AU - Bradley, Maria
AU - Sommar, Lena Holm
AU - Ivert, Lina
AU - Johansson, Emma K.
AU - Josefson, Anna
AU - Lundeberg, Lena
AU - Lundqvist, Maria
AU - Nylander, Elisabet
AU - Sandström-Falk, MariHelen
AU - Shayesteh, Alexander
AU - Sigurdardottir, Gunnthorunn
AU - Sonesson, Andreas
AU - Svedbom, Axel
AU - Svensson, Åke
AU - Virtanen, Marie
AU - von Kobyletzki, Laura
AU - Vrang, Sophie
AU - Wahlgren, Carl-Fredrik
AU - Corazza, Monica
AU - Esposito, Maria
AU - Fabbrocini, Gabriella
AU - Fargnoli, Maria Concetta
AU - Ferrucci, Silvia M.
AU - Foti, Caterina
AU - Girolomoni, Giampiero
AU - Hansel, Katharina
AU - Marzano, Angelo V.
AU - Napolitano, Maddalena
AU - Passante, Maria
AU - Patruno, Cataldo
AU - Peris, Ketty
AU - Pigatto, Paolo Daniele
AU - Romanelli, Marco
AU - Romita, Paolo
AU - Rossi, Mariateresa
AU - Schena, Donatella
AU - Schettini, Natale
AU - Tonini, Giulia
N1 - Publisher Copyright:
© 2025 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
PY - 2025/12
Y1 - 2025/12
N2 - Background: The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE). Objectives: This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe. Methods: Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium). Results: The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4. Conclusions: This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.
AB - Background: The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE). Objectives: This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe. Methods: Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium). Results: The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4. Conclusions: This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.
KW - atopic dermatitis
KW - atopic eczema
KW - baseline
KW - demographics
KW - disease burden
KW - disease severity
KW - patient-reported outcomes
KW - phototherapy
KW - real-world data
KW - registry
KW - systemic immunomodulating treatment
UR - https://www.scopus.com/pages/publications/105013855252
U2 - 10.1111/jdv.20876
DO - 10.1111/jdv.20876
M3 - Article
C2 - 40832875
SN - 0926-9959
VL - 39
SP - 2096
EP - 2112
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 12
ER -